Podcasts about therapies

Send us a textJoin Dr. Daphna Yasova Barbeau as she kicks off The Incubator's live coverage from the Children's Hospitals Neonatal Consortium (CHNC) 2025 Symposium in Denver. This opening episode sets the stage for two days of conversations focused on improving care for high-risk infants through data sharing, collaboration, and quality improvement across Level IV NICUs. Daphna introduces the mission behind CHNC and its powerful Children's Hospitals Neonatal Database (CHND)—a resource driving benchmarking and innovation nationwide. Tune in for context, purpose, and the energy that fuels this year's meeting before diving into interviews with CHNC leaders and attendeesSupport the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Listen as Matthias Kretzler, MD, Julio Saez-Rodriguez, PhD, and Katalin Susztak, MD, PhD, discuss advancements and challenges in research during the episode "Future Therapies: Science Shaping Tomorrow's Kidney Care."

Listen as Matthias Kretzler, MD, Julio Saez-Rodriguez, PhD, and Katalin Susztak, MD, PhD, discuss advancements and challenges in research during the episode "Future Therapies: Science Shaping Tomorrow's Kidney Care."

CardioNerds kicks off its advanced therapies series with Chair of the CardioNerds Heart Failure Council, Dr. Jenna Skowronski, co-chair of the series, Dr. Shazli Khan, and Episode FIT lead, Dr. Jason Feinman. In this first episode, they discuss the process of advanced therapies evaluation with Dr. Michelle Kittleson, Professor of Medicine and Director of Education in Heart Failure and Transplantation at Cedars-Sinai. In this case-based discussion, they cover the signs and symptoms of end-stage heart failure, the initial management strategies, and the diagnostic workup required when considering advanced therapies. Importantly, they discuss the special considerations for pursuing left-ventricular assist device (LVAD) versus heart transplantation as well as the multidisciplinary, team-based approach needed when advanced therapies are indicated.  Notes were drafted by Dr. Shazli Khan.  Audio editing for this episode was performed by CardioNerds Intern, Julia Marques Fernandes. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Heart Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls Guideline-directed medical therapy (GDMT) is indicated in all heart failure patients and improves survival, but progressive symptoms and intolerance to GDMT can be warning signs of disease progression. The I-NEED-HELP mnemonic is an excellent reference when considering referral for advanced therapies (Figure).   Management of acute decompensation includes diuretics and possible inotropic support. The inotropic agent used should be whichever best suits your specific patient. Milrinone may result in more hypotension, whereas dobutamine may result in more tachycardia. Tachycardic and normotensive patients may do better with milrinone, while hypotensive patients with normal heart rates may do better with dobutamine. Notably, DoReMi found no difference between milrinone and dobutamine for patients with cardiogenic shock.  The initial diagnostic evaluation includes an echocardiogram, right heart catheterization (RHC), and often cardiopulmonary exercise testing (CPET) to objectively assess the status of the heart. Comprehensive labs, imaging and cancer screening are also needed to assess all other organs.   When making the decision to pursue advanced therapies, always ask:   Is the heart sick enough?   Is the rest of the body well enough?   These two questions provide a framework to guide if patients are optimal candidates for transplant versus LVAD.   The advanced therapies evaluation is a team sport! Patients will meet not only with advanced heart failure cardiologists, but also cardiac surgeons, psychiatrists, social workers, nutritionists and pharmacists. All team members are of critical value in the process.   Notes 1.) What are the key features of advanced cardiomyopathy, and when should providers consider referral for advanced therapies?   Advanced cardiomyopathy may present as recurrent hospitalizations for decompensated heart failure, intolerance to GDMT with symptomatic orthostasis and hypotension, and progressive symptoms of heart failure despite medical therapy.   The I-NEED-HELP mnemonic is a helpful tool to identify patients at risk of heart failure and is defined as follows: Need for Inotropic support, New York Heart Association (NYHA) Class IV symptoms, End-Organ Dysfunction, Ejection fraction

Prostate cancer is one of the most common cancers in men. While treatment options have improved, advanced stages of the disease remain difficult to manage. One promising approach involves a process called ferroptosis. This is a type of programmed cell death that relies on iron and lipid oxidation to kill cancer cells by damaging specific fats in their outer membrane. These fats are especially vulnerable in environments with normal oxygen levels. However, many prostate tumors grow in low-oxygen areas of the body, a condition known as hypoxia, where ferroptosis becomes less effective. A recent study, titled “Hypoxia induced lipid droplet accumulation promotes resistance to ferroptosis in prostate cancer,” and published on Oncotarget (Volume 16), explores how oxygen-poor environments help prostate cancer cells resist treatment and what strategies could help overcome this resistance. Full blog - https://www.oncotarget.org/2025/11/06/how-low-oxygen-shields-prostate-cancer-from-ferroptosis-therapies/ Paper DOI - https://doi.org/10.18632/oncotarget.28750 Correspondence to - Noel A. Warfel - warfelna@arizona.edu, and Shailender S. Chauhan - shailenderc@arizona.edu Abstract video - https://www.youtube.com/watch?v=xFypDT4ALmc Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28750 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, hypoxia, lipid droplets, ferroptosis, resistance, prostate To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Alicia Silver, senior director at ADVI Health, highlights the evolving landscape of cell and gene therapy and the need to improve patient access and payment for these treatments. Availability of these therapies for solid tumors and genetic diseases like sickle cell disease is expanding due to the transition from inpatient to outpatient and community settings. The FDA's decision to remove REMS requirements for specific therapies has accelerated the growth of facilities to provide care, particularly for vulnerable populations. Alicia explains, "We work with a number of different cell and gene therapy clients throughout the sector. So we work with manufacturers who have commercialized cell and gene therapy products. So they have products that are currently on the market, manufacturers who are going through the process of clinical trials right now, working with the FDA to get approved products. But we also work with trade organizations that are working behind the scenes at the sector level, trying to get different policies and access changes for patients."   "To date, there's probably close to a couple of dozen FDA-approved cell and gene therapies, and they treat everything from blood cancers, which were the first approvals in something called CAR T. We saw blood cancers as the first approvals, and then everything through to solid tumors in oncology. But also, we have newer gene therapies for conditions like sickle cell disease. And that's an area that's been incredibly underserved and definitely will benefit from a durable gene therapy that hopefully corrects some of the issues that patients with sickle cell disease have, like pain crises that end up in a hospital. So from that perspective, we see a really wide range of treatments available to patients today and many more on the horizon." "I think the price tag is definitely somewhat of sticker shock for people who don't understand how cell and gene therapy products are valued. And so what we do a lot of times, educating on, is helping payers understand that it's not necessarily $2 million for a treatment that's going to be a recurrent payment, but something that's kind of an investment in the patient's and the plan's future." #ADVIHealth #CellTherapy #GeneTherapy #AcesstoCellGeneTherapy #ClinicalTrials  advi.com Listen to the podcast here

Alicia Silver, senior director at ADVI Health, highlights the evolving landscape of cell and gene therapy and the need to improve patient access and payment for these treatments. Availability of these therapies for solid tumors and genetic diseases like sickle cell disease is expanding due to the transition from inpatient to outpatient and community settings. The FDA's decision to remove REMS requirements for specific therapies has accelerated the growth of facilities to provide care, particularly for vulnerable populations. Alicia explains, "We work with a number of different cell and gene therapy clients throughout the sector. So we work with manufacturers who have commercialized cell and gene therapy products. So they have products that are currently on the market, manufacturers who are going through the process of clinical trials right now, working with the FDA to get approved products. But we also work with trade organizations that are working behind the scenes at the sector level, trying to get different policies and access changes for patients."   "To date, there's probably close to a couple of dozen FDA-approved cell and gene therapies, and they treat everything from blood cancers, which were the first approvals in something called CAR T. We saw blood cancers as the first approvals, and then everything through to solid tumors in oncology. But also, we have newer gene therapies for conditions like sickle cell disease. And that's an area that's been incredibly underserved and definitely will benefit from a durable gene therapy that hopefully corrects some of the issues that patients with sickle cell disease have, like pain crises that end up in a hospital. So from that perspective, we see a really wide range of treatments available to patients today and many more on the horizon." "I think the price tag is definitely somewhat of sticker shock for people who don't understand how cell and gene therapy products are valued. And so what we do a lot of times, educating on, is helping payers understand that it's not necessarily $2 million for a treatment that's going to be a recurrent payment, but something that's kind of an investment in the patient's and the plan's future." #ADVIHealth #CellTherapy #GeneTherapy #AcesstoCellGeneTherapy #ClinicalTrials  advi.com Download the transcript here

Please visit answersincme.com/XCG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. This educational activity brings together leading experts in ophthalmology and oncology to explore clinical strategies for managing ocular adverse events associated with a novel class of therapies for advanced breast cancer: the oral selective estrogen receptor degraders (SERDs). Faculty will share key insights and practical guidance on identifying and managing common ocular side effects—particularly photopsia and dry eye—with the goal of enhancing patient care and improving quality of life for individuals navigating survivorship with advanced breast cancer. Upon completion of this activity, participants should be better able to: Recognize the implications of using oral SERDs in HR-positive, HER2-negative breast cancer for ophthalmic practice; Describe the ocular toxicities associated with oral SERDs used in breast cancer treatment; and Apply multidisciplinary strategies to facilitate the detection and management of ocular toxicities in patients receiving oral SERDs.

Please visit answersincme.com/XCG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. This educational activity brings together leading experts in ophthalmology and oncology to explore clinical strategies for managing ocular adverse events associated with a novel class of therapies for advanced breast cancer: the oral selective estrogen receptor degraders (SERDs). Faculty will share key insights and practical guidance on identifying and managing common ocular side effects—particularly photopsia and dry eye—with the goal of enhancing patient care and improving quality of life for individuals navigating survivorship with advanced breast cancer. Upon completion of this activity, participants should be better able to: Recognize the implications of using oral SERDs in HR-positive, HER2-negative breast cancer for ophthalmic practice; Describe the ocular toxicities associated with oral SERDs used in breast cancer treatment; and Apply multidisciplinary strategies to facilitate the detection and management of ocular toxicities in patients receiving oral SERDs.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore a series of groundbreaking advancements and strategic collaborations that promise to transform drug development and patient care.In the autoimmune space, Boehringer Ingelheim has made a significant move by securing a $570 million agreement with CDR-Life. This deal centers on a trispecific antibody, a novel therapeutic approach that targets multiple pathways simultaneously, potentially revolutionizing treatments for autoimmune diseases. Boehringer's commitment to these cutting-edge modalities highlights their strategy to leverage novel technologies for more effective therapeutic solutions.Similarly, Celltrion has entered a $744 million collaboration with Kaigene, focusing on two preclinical autoimmune drugs. This partnership marks Celltrion's strategic shift from biosimilars to novel biologics, positioning the company at the forefront of biologic therapeutics. By investing in early-stage research, Celltrion aims to introduce transformative therapies for autoimmune conditions, showcasing the industry's willingness to bet on groundbreaking scientific advancements.In gene editing, Azalea Therapeutics is gaining attention with its focus on permanent genome editing using a dual-vector approach. Backed by $82 million in funding and support from CRISPR pioneer Jennifer Doudna, Azalea is poised to develop potentially curative solutions through single-dose treatments. The credibility lent by a Nobel laureate adds anticipation to their research outcomes, with the potential to significantly impact gene therapy.Shifting focus to clinical trials, Sarepta Therapeutics faces challenges after missing the primary endpoint in its confirmatory trial for Duchenne muscular dystrophy drugs. Despite this setback, Sarepta is pursuing full FDA approval, emphasizing the complex interplay between clinical data and regulatory strategies. This situation underscores the critical importance of robust confirmatory trials in securing drug approvals and ensuring patient access to new therapies.Merck is making strategic moves in oncology by regaining full control over an early-phase asset and securing $700 million from Blackstone for its oncology pipeline. This dual focus on asset acquisition and financial fortification reflects Merck's aggressive growth strategy aimed at expanding its cancer treatment offerings.Emerging from stealth mode, Neok Bio has secured a $75 million investment to advance bispecific antibody-drug conjugates into clinical trials. These bispecific ADCs represent the forefront of targeted cancer therapies, aiming for precision targeting of cancer cells while minimizing off-target effects. Neok Bio's progress could significantly enhance oncology treatment paradigms through improved therapeutic indices.Turning to regulatory landscapes, Teva's recall of over half-a-million bottles of prazosin hydrochloride due to potential carcinogenic impurities highlights ongoing challenges in ensuring drug safety and quality control within manufacturing processes. Such recalls underscore the critical importance of maintaining high standards in pharmaceutical production.In broader industry developments, we see dynamic trends where scientific innovation meets strategic business decisions and regulatory considerations. The potential impact on patient care is profound, with breakthroughs in autoimmune treatments, gene editing technologies, and targeted cancer therapies poised to alter therapeutic landscapes significantly.UCB has achieved another milestone with FDA approval for Kygevvi, an ultra-rare disease medication marking their third approval in rare conditions within three years. This success underscores UCB's strategic focus on niche markets that offer less competition but significant patient impact. Advancements in genetic research aSupport the show

Here's a polished podcast blurb suitable for LinkedIn, BlueSky, or Apple Podcasts listings — written in the JIMD Podcast tone and style: ⸻ It's one of the most talked-about breakthroughs of 2025, a first-in-human demonstration of in vivo gene editing to treat an inherited metabolic disease. In this episode, Kiran Musunuru and Rebecca Ahrens-Nicklas are joined by Julien Baruteau to unpack what this means for the field. They explore the science behind gene editing, the importance of ethical design, and the emotional weight of stopping therapy once enzyme function is restored. The conversation bridges the NEJM landmark paper (Musunuru et al., 2025) and the accompanying JIMD editorial (Rahman & Baruteau, 2025), reflecting on what this moment tells us about the future of metabolic medicine and how ready we are for it. First in Human Gene Editing for an Inherited Metabolic Disease Shamima Rahman, Julien Baruteau https://doi.org/10.1002/jimd.70056 Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease Kiran Musunuru, et al https://www.nejm.org/doi/10.1056/NEJMoa2504747

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/FRU865. CME/NCPD/CPE credit will be available until October 26, 2026.Implementing Targeted Therapies in Transthyretin Cardiac Amyloidosis: From Diagnosis to Stabilization In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from BridgeBio Pharma, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/FRU865. CME/NCPD/CPE credit will be available until October 26, 2026.Implementing Targeted Therapies in Transthyretin Cardiac Amyloidosis: From Diagnosis to Stabilization In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from BridgeBio Pharma, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/FRU865. CME/NCPD/CPE credit will be available until October 26, 2026.Implementing Targeted Therapies in Transthyretin Cardiac Amyloidosis: From Diagnosis to Stabilization In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from BridgeBio Pharma, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/FRU865. CME/NCPD/CPE credit will be available until October 26, 2026.Implementing Targeted Therapies in Transthyretin Cardiac Amyloidosis: From Diagnosis to Stabilization In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from BridgeBio Pharma, Inc.Disclosure information is available at the beginning of the video presentation.

In this podcast, Andrea Burgess discusses her paper 'Active upper-limb therapies for hand function, individual goal achievement, and selfcare in children with cerebral palsy: A network meta-analysis'. The paper is available here: https://doi.org/10.1111/dmcn.16476 Follow DMCN on Podbean for more: https://dmcn.podbean.com/ ___ Watch DMCN Podcasts on YouTube: https://bit.ly/2ONCYiC __ DMCN Journal: Developmental Medicine & Child Neurology (DMCN) has defined the field of paediatric neurology and childhood-onset neurodisability for over 60 years. DMCN disseminates the latest clinical research results globally to enhance the care and improve the lives of disabled children and their families. DMCN Journal - https://onlinelibrary.wiley.com/journal/14698749 ___ Find us on Twitter! @mackeithpress - https://twitter.com/mackeithpress

Today we are bringing you a conversation on how topical therapies can effectively manage atopic dermatitis. Brian Keegan, MD, PhD, FAAD, a dermatologist with Princeton Dermatology, spoke with Alexa Hetzel, MS, PA-C, physician assistant with Schweiger Dermatology Group; Vikash D. Oza, MD, director of pediatric dermatology at NYU Langone; and Amy Spizuoco, DO, FAOCD, dermatologist and dermatopathologist at True Dermatology. In addition to discussing the clinical benefits and impact on patient outcomes of using topical therapies for atopic dermatitis, the panelists explored how health economics research informs treatment decisions by demonstrating the cost-effectiveness and accessibility of topical therapies. The panel also analyzed the potential health care cost savings and resource optimization achieved through strategic use of topical treatments and atopic dermatitis management.

Send us a textDr. Fred Grossman, D.O., FAPA is President and Chief Medical Officer of Coya Therapeutics ( https://coyatherapeutics.com/ ), a clinical-stage company focused on developing multi-modality, Regulatory T Cell (Treg) therapies for neurodegenerative diseases. Coya has already developed strong proof of concept data in Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's, and is also active in the autoimmune and metabolic disease domains.Dr. Grossman brings over 20 years of drug development expertise having held senior executive leadership positions in large and small pharmaceutical companies, leading the development and FDA approval of numerous multi-billion dollar blockbuster drugs addressing significant unmet medical needs particularly across CNS disorders. He has close relationships with thought leaders worldwide and has negotiated directly with the FDA and Global Health Authorities for approval of many drugs across therapeutic areas. Dr. Grossman held executive positions at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, and Sunovion. He served as President and Chief Medical Officer at Glenmark Pharmaceuticals, a $1.5 Billion per annum global pharmaceutical company based in India, overseeing development of an entire pipeline including generics, complex generics including 505(b)(2) candidates, and next-generation biologics (including bi-specific antibodies). Dr. Grossman also previously served as Chief Medical Officer at Mesoblast, Inc., developing allogeneic cellular therapies for inflammatory diseases. Dr. Grossman is Board-Certified in Psychiatry and a Fellow of the American Psychiatric Association and was a Fellow at the National Institutes of Health (NIH). He has held several academic appointments and authored numerous scientific publications.#RegulatoryTCells #Tregs #AutoimmuneDisorders #ShimonSakaguchi #ImmuneSystem #FredGrossman #CoyaTherapeutics #NeurodegenerativeDiseases #AmyotrophicLateralSclerosis #ALS #Alzheimers #CNSDisorders #StanleyAppel #Immunomodulation #ProInflammatoryCytokines #SelfTolerance #Microglia #Macrophages #CTLA4Ig #LowDoseIl2 #FusionProtein #ImmuneCheckpointModulator #FrontotemporalDementia #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Research is more than just finding interesting stats. It's about finding better ways to deliver savings, simplicity, and support. In this episode, you'll hear from managed care pharmacy researchers who are doing just that, delivering data driven insights to drive affordability and access in health care.  Pat Gleason, PharmD, BCPS, FCCP, FAMCP, assistant vice president of health outcomes; Nick Friedlander, PharmD, clinical program pharmacist; and Simone Ndujiuba, PharmD, BCOP, clinical oncology pharmacist senior principal; and host Alex Cook, senior public relations manager, discuss how Prime's research helps address affordability and accessibility issues and guides health care providers and peers toward clarity on treatment for complex health conditions. Research topics covered:Three-Year Real-World Adherence and Persistence to Glucagon-Like Peptide-1 Receptor Agonists Among Commercially Insured Adults with Obesity without Diabetes Trends in Real-World Persistence to Weight Loss Glucagon-Like Peptide-1 Receptor Agonists from 2021 to 2024 Among Commercially Insured Adults without Diabetes — This study earned a platinum award from AMCP.  Impact of a Medical Claims Automated Glucagon Like Peptide-1 Drugs Prior Authorization Program— This study earned a gold award from AMCP.Validation of Long-term Savings from a Pharmacist-to-Prescriber Telephonic Intervention — This study earned a gold award from AMCP. Total Cost of Care and Adverse Effects Assessment of Bispecific T-cell Engagers and Chimeric Antigen Receptor T-cell Therapies for Relapsed Refractory Follicular Lymphoma  -------------------------Content in this podcast is for informational or educational purposes only.The content also does not substitute professional medical advice or consultations with health care professionals. Always seek advice from a physician or other health care providers with any questions you have regarding a medical treatment or condition before undertaking a new health care regimen.

Are you secretly running on anxiety, even as everyone praises your productivity, drive, and ability to “do it all”? I'm joined by an award-winning psychologist, Dr. Lalitaa Suglani, who breaks down the difference between being simply driven and silently battling high-functioning anxiety—a line so thin, most of us don't even realize we've crossed it.We'll dive deep into what high-functioning anxiety really is, how it hides behind ambition, and why so many busy, successful women are silently caught in its grip. Dr. Lalitaa reveals how childhood patterns might still be running the show, why saying “yes” is sometimes a sign you're feeling “not enough,” and how external success can actually keep you stuck in survival mode. You'll find out what high-functioning anxiety really looks like from the inside out, how it might be showing up in your body, and the practical next steps to help you break free from the overwhelming cycle without sacrificing your ambition or success. By the end of the episode, you'll have the tools to start drawing boundaries and understanding your triggers so you can stay ambitious without the constant wave of stress, guilt, or shame. Hit play and let's dive in.4:53 – What High Functioning Anxiety Really Looks Like for High Achievers11:02 – How Childhood Experiences Shape Adult Anxiety 18:58 – How to Spot the Difference Between Being Driven or Overwhelmed and the External Red Flags of High-Functioning Anxiety 24:11 – The First Real Step to Feeling Better (It's NOT Just Slowing Down)28:57 – The Tools and Therapies that Actually Help and How to Find Support32:36 – What Life After Healing From High-Functioning Anxiety Can Look Like Episode Links:Connect with Dr. Lalitaa: Website | InstagramGrab Dr. Lalitaa's book on High-Functioning Anxiety

In this insightful podcast episode, I chat with Dr. Shahrzad Jalai, an accomplished clinical psychologist with a rich background in linguistics and a deep interest in holistic therapy approaches. Our conversation traverses her personal and professional journey, offering profound insights into the nuances of trauma, innovative therapy techniques, and the fascinating convergence of the body and the psyche. What You'll Learn: Integration of Linguistics in Psychology: Discover how Dr. Jalai transitioned from linguistics to psychology and how her background enriches her clinical practice. Understanding Soul Searching: Hear Dr. Jalai's personal story of transformation through therapy and her eventual foray into psychology. Current Trends in Psychological Health: Insights into the growing trend of emotional dysregulation and the quest for safety among clients. Psyche-Body Connection: Explore the role of the nervous system in mental health and Dr. Jalai's holistic approach to therapy. Jungian Psychology & Dreams: Learn about Jung's philosophies, the interplay of dreams and the unconscious, and how they shape therapeutic strategies. Psychoanalytic vs. Cognitive Therapies: A clear distinction between the objective, structured cognitive approaches and the depth-oriented psychoanalytic therapies. Spotlight on Complexes: Uncover the understated influence of complexes from childhood on our adult life, and the therapeutic exploration of these hidden forces. Somatic Approaches to Trauma: Dive into the methodologies like EMDR and Brainspotting used to integrate physiological responses in treating psychological traumas. Key Takeaways: Trauma is not only processed through the mind but is deeply stored within the body, necessitating a holistic treatment approach. Therapies focused on unity and compassion are vital in bridging human chaos and disconnect, offering pathways to greater personal and societal harmony. Exploring personal traumas and histories provides an opportunity not only for healing but also for uncovering the wisdom and strengths gained through adversity. Professionals must navigate transference carefully to maintain personal well-being and effective therapeutic outcomes. Acknowledging and addressing the interconnectedness of body and mind can significantly enhance the efficacy of psychological interventions. Resources For those interested in delving deeper into Dr. Jalai's transformative work, her book "The Fire That Makes Us" weaves personal and clinical insights into a compelling narrative of healing through trauma. Additionally, her upcoming course "Regulate to Rise" offers practical strategies for nervous system regulation, providing tangible tools for those seeking to improve their mental health. Further information, educational materials, and resources from Dr. Jalai can be found on her website and through her social media platforms, aligning the learnings from this podcast into actionable steps for personal growth and healing. https://alignremedy.com/ https://www.instagram.com/alignremedy https://www.youtube.com/@alignremedy Tiktok: @Dr.jalalipsyd LinkedIn: https://www.linkedin.com/in/shahrzad-jalali-psyd-2b547320/ Support the Podcast If you found this conversation enriching and beneficial, subscribe, rate, and review us on your favourite podcast platform. Your support spreads these essential dialogues, offering more individuals the opportunity to embark on their healing journeys. Share this episode with anyone navigating their own struggles—this discussion could be the guiding light they seek in understanding and overcoming personal trauma. 00:23 Transition from Linguistics to Psychology 02:51 Trends in Clinical Psychology 04:06 The Role of the Nervous System in Mental Health 06:50 Jungian Psychology and Dream Analysis 10:29 Cognitive vs. Analytical Psychology 14:14 Childhood Influences on Adult Complexes 19:38 Somatic Approaches to Trauma 22:16 Understanding EMDR and Brainspotting 25:00 Understanding PTSD and EMDR 25:43 Introduction to Brainspotting 27:32 Self-Spotting Techniques 28:35 Breath Work and Emotional Release 31:21 Holotropic Breathing and Trauma 36:10 Personal Journey and Writing 41:57 The Healing Power of Therapy 44:57 Future of Psychology and Personal Growth See omnystudio.com/listener for privacy information.

A Nemours neurologist receives a prestigious grant from the National Institutes of Health.The funding will be used to study brain patterns that could lead to shared therapies for autism, epilepsy and Alzheimer's disease patients.On this edition of Enlighten Me, Delaware Public Media's Joe Irizarry sits down with Nemours Children's Health Chief of Neurology Dr. Rodney Scott to discuss how his work can help patients.

Is there really one “right” therapy?Or are we just drowning in Google searches, hoping to crack the magical code that will lead to our child finally hitting that big milestone like walking, talking, or finally sleeping through the dang night?So many of us special needs moms fall into the trap of thinking there's one golden-ticket treatment out there. That if we research hard enough, fight hard enough, do enough… we'll find the thing that unlocks all the milestones.But that mindset is the fast track to burnout.In this episode, we're talking about how to think about therapies, early interventions, and what actually helps (hint: it's not just one magic answer). 

Ditching the word psychedelic is helping employers embrace therapies that show "groundbreaking results" including faster recovery and more productive employees, explains Sherry Rais, CEO and co-founder of Enthea, in this episode. In addition to health improvements, these therapies can lead to lower healthcare costs and lower disability costs. Hear more about psychedelic-assisted therapies that can be effective with treatment-resistant patients as well as promising research studies underway in this episode of the DMEC podcast.Resources:From Counterculture to Clinical Treatment, article in @Work magazine (open to the public)What Role Should Health Equity Have in Benefit Discussions?How Can Employers Prepare for Psychedelics?Mentioned in this episode:Are Leave Management Specialists Asking the Right Questions?Increase Your Professional Value. Become a Certified Leave Management Specialist Today: https://dmec.org/certification-and-training/clms-certification/DMEC

Did you know that approximately 50% of breast cancer patients who have been exposed to an aromatase inhibitor (AI) over time in the metastatic setting develop an ESR1 mutation? Credit available for this activity expires: 10/17/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1003008?ecd=bdc_podcast_libsyn_mscpedu

New FDA-approved therapies for BCG-refractory non-muscle invasive bladder cancer (NMIBC)–where do they fit in the treatment algorithm, and how do you administer them? This installment of the 2025 NMIBC Creator Weekend™ series features host Dr. Bogdana Schmidt, assistant professor of Urologic Oncology at the University of Utah, and leading urologic oncologists Dr. Mark Tyson from Mayo Clinic Arizona and Dr. Suzanne Merrill from Colorado Urology.---This podcast is supported by:Ferring Pharmaceuticalshttps://www.ferring.com/home-classic/people-and-families/uro-uro-oncology/bladder-cancer/---SYNPOSISThe discussion delves into the newest treatment strategies and FDA-approved therapies for non-muscle invasive bladder cancer with an emphasis on BCG-refractory patients. They highlight their approaches to sequencing therapies, the real-world applicability of these treatments, and the impact of patient factors in clinical decision-making. The panel also explores emerging trials and innovative treatment mechanisms, emphasizing the importance of personalized care in oncology.---TIMESTAMPS00:00 - Introduction05:09 - Challenges and Strategies in Treatment10:55 - Bladder Sparing Therapies21:41 - Practical Tips for Therapy Administration30:39 - Challenges and Considerations in Reinduction37:05 - Clinical Trials and Future Directions44:11 - Counseling Patients on Treatment Options57:36 - Concluding Thoughts and Future Outlook---RESOURCESCORE-008 Clinical Trial https://www.sciencedirect.com/science/article/abs/pii/S1078143924010147Legend Clinical Trial:https://ascopubs.org/doi/10.1200/JCO.2025.43.5_suppl.802CISTO Studyhttps://pubmed.ncbi.nlm.nih.gov/37980511/

Frequency medicine uses electromagnetic fields to support cellular wellness. This episode explores the science behind PEMF, bioresonance, and infrared therapies, examining research findings and how modern wellness systems integrate these technologies for home and clinical use.To learn more, visit: https://quanivowellness.com/product-details/product/bio-wellness-energy-bed Quanivo LLC City: Carlsbad Address: 7040 Avenida Encinas Website: https://quanivowellness.com/ Phone: +1 760 203 6399 Email: hello@quanivo.com

Genetic counsellors Matt and Sandra explore Huntington disease, prenatal and lab-based testing ethics, and how lab genetic counsellors act as gatekeepers. They discuss exclusion testing, the challenges of writing clear lab reports, and recent advances in gene therapy. The episode also covers the growing role of AI and automation in genetic labs, the evolving responsibilities of lab GCs, and how testing impacts life choices like career planning and family decisions.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/CXX865. CME/NCPD credit will be available until September 18, 2026.Preparing Your Practice for Amyloid-Directed Therapies in Alzheimer's Disease: Key Strategies to Enhance Early Diagnosis and Optimize Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant by Eisai Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/CXX865. CME/NCPD credit will be available until September 18, 2026.Preparing Your Practice for Amyloid-Directed Therapies in Alzheimer's Disease: Key Strategies to Enhance Early Diagnosis and Optimize Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant by Eisai Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/CXX865. CME/NCPD credit will be available until September 18, 2026.Preparing Your Practice for Amyloid-Directed Therapies in Alzheimer's Disease: Key Strategies to Enhance Early Diagnosis and Optimize Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant by Eisai Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/CXX865. CME/NCPD credit will be available until September 18, 2026.Preparing Your Practice for Amyloid-Directed Therapies in Alzheimer's Disease: Key Strategies to Enhance Early Diagnosis and Optimize Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant by Eisai Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/CXX865. CME/NCPD credit will be available until September 18, 2026.Preparing Your Practice for Amyloid-Directed Therapies in Alzheimer's Disease: Key Strategies to Enhance Early Diagnosis and Optimize Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant by Eisai Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/CXX865. CME/NCPD credit will be available until September 18, 2026.Preparing Your Practice for Amyloid-Directed Therapies in Alzheimer's Disease: Key Strategies to Enhance Early Diagnosis and Optimize Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant by Eisai Inc.Disclosure information is available at the beginning of the video presentation.

Welcome to The Superhumanize Podcast. I'm your host, Ariane Sommer, and today we're diving into one of the most paradigm-shifting conversations in modern medicine: the metabolic theory of cancer.For decades, we've been told that cancer is primarily a genetic disease, a matter of unlucky mutations that require aggressive pharmaceutical interventions. But what if that's only part of the story? What if cancer is fundamentally a metabolic disease, a disorder of cellular energy production that we can address through diet, lifestyle, and targeted metabolic therapies?This isn't fringe science. And it's giving patients new hope, and new options, beyond the standard cut, poison, and burn model. Today, I'm thrilled to welcome Dr. Donese Worden to the show. Dr. Worden is a board-certified Naturopathic Medical Doctor, researcher, and global health educator who has dedicated her career to bridging conventional and alternative cancer care. She's collaborated with Banner MD Anderson Cancer Center, served as CEO of Care Oncology, and works directly with Dr. Seyfried on metabolic cancer research. She's also the creator of the 7 Pillars of Health framework, a comprehensive approach to resilience that addresses everything from sleep and gut health to spiritual wellbeing.Dr. Worden's motto is 'Educate, Empower, Enlighten,' and that's exactly what we're going to do today. We'll explore the metabolic theory of cancer, discuss both prevention and treatment strategies, and give you a roadmap for building resilience at every level.Episode Highlights00:00 Welcome + why the “metabolic theory of cancer” matters02:00 Genetics vs. metabolism: why only ~5% is strictly genetic (and gene expression is modifiable)03:45 Warburg's mitochondrial lens; PET scans lighting up because cancer voraciously consumes sugar06:45 How we veered away historically; incentives that kept oncology gene-centric09:00 What damages mitochondria today: toxins, antibiotics (without mitigation), chronic stress10:30 Stress as a metabolic driver; why it keeps glucose high even on a “good” diet12:30 Ketogenic therapy for cancer: high fat, lower protein (individualized), carbs mainly from veggies15:00 Measuring correctly: Keto-Mojo, GKI (Glucose-Ketone Index); skip urine strips for accuracy17:00 Fast stress relief protocols: music-guided entrainment, breath work, active meditation, journaling20:15 Somatic breath work in practice; rapid emotional release21:00 Best fats and how Dr. W screens with food-sensitivity testing first23:15 Keto cycles for prevention: 6-week blocks a couple times per year24:15 Exercise as mitochondrial medicine: HIIT + resistance for biogenesis and cancer risk reduction26:00 The KetoPet model: ketogenic diet + HBOT + interval training; lessons for humans28:15 Starting movement in late-stage cases; meeting people exactly where they are30:15 “Press–Pulse” strategy: what stays constant vs. what's pulsed to outsmart tumor adaptation32:00 Repurposed meds (e.g., metformin, doxycycline) and why many oncologists can't step outside SOC33:00 Bridging care: when surgery/chemo/radiation have a role; aiming at cancer stem cells37:15 Hyperbaric oxygen therapy (HBOT): driving O₂ into cells; why it's pulsed and protocol-specific39:30 Outcomes Dr. W sees most consistently: better quality of life, often longer survival41:00 The psychology of prognosis; belief, stress, and manifestation43:00 The “placebo” as your body's own pharmacy (parasympathetic healing state)44:15 Targeting glutamine along with glucose; where evidence stands now (e.g., berberine, exercise, stress)46:45 The Seven Pillars of Health overview (self-audit)48:30 Pillar 1 — Sleep: deep/REM, how you feel on waking49:15 Pillar 2 — Body: strength,...

From CAR-T therapies to viral vectors, cell and gene treatments are redefining the boundaries of pharmacy practice—but with innovation comes complexity. Host Carolyn Liptak welcomes Dr. Mark Wiencek, Principal Microbiologist with the Technical Services Group at Contec, and Dr. Amanda Frick, Senior Clinical Manager of Market Intelligence at Vizient, to break down the challenges of compounding these advanced therapies.   Listen in as they discuss real-world risk assessments, biosafety considerations, and how hospital pharmacies can safely manage these groundbreaking yet high-risk treatments.   Guest speakers:  Mark Wiencek, PhD Principal Microbiologist, Technical Services Group Contec Amanda Frick, PharmD, BCPS Senior Clinical Manager, Market Intelligence Vizient   Host:  Carolyn Liptak, MBA, RPh  Pharmacy Executive Director  Vizient   Show Notes:  [01:02-01:51] Mark shares his background and experience in microbiology [01:52-04:04] Overview of the types of cell and gene therapies (CGT) currently used in clinical practice [04:05-05:14] Which CGT therapies are most applicable to pharmacy compounding and why [05:15-10:29] Things not on the NIOSH list and the risks [10:30-12:03] Evaluating whether viral vectors can penetrate intact skin and the true occupational exposure risks [12:04-13:18] If hazards are not defined by the NIOSH list, how should these CGT hazards be classified [13:19-15:03] Determining the safest environment for compounding CGT therapies [15:04-20:14] Best practices for decontamination, disinfection, and viral vector handling [20:15-20:59] Do you need a dedicated biosafety cabinet for CGT therapies [21:00-22:55] Recommended resources for further learning   Links | Resources:   Blind and colleagues (Nationwide): Click here Wang and colleagues (Stanford): Click here CONTEC HEALTHCARE WEBINAR Using Bugs as Drugs: Compounding Viral Vectors in Cell & Gene Therapy for Hospital Pharmacies, Mark Wiencek, May 13, 2025: Click here Blind, J.E., Ghosh, S., Niese, T.D., Gardner, J.C., Stack-Simone, S., Dean, A. and Washam, M., 2024. A comprehensive literature scoping review of infection prevention and control methods for viral-mediated gene therapies. Antimicrobial Stewardship & Healthcare Epidemiology, 4(1), p.e15. Click here Deramoudt, L., Pinturaud, M., Bouquet, P., Goffard, A., Simon, N. and Odou, P., 2024. Method for the detection and quantification of viral contamination during the preparation of gene therapy drugs in a hospital pharmacy. Occupational and Environmental Medicine, 81(12), pp.615-621. Click here Korte, J., Mienert, J., Hennigs, J.K. and Körbelin, J., 2021. Inactivation of adeno-associated viral vectors by oxidant-based disinfectants. Human Gene Therapy, 32(13-14), pp.771-781. Click here (abstract only; full article available for purchase) Martino, J.G., McConnell, K., Greathouse, L., Rosario, B.D. and Jaskowiak, J.M., 2024. Cellular therapy site-preparedness: Inpatient pharmacy implementation at a large academic medical center. Journal of Oncology Pharmacy Practice, 30(8), pp.1442-1449. Click here Penzien, C., 2023. Safe handling of BioSafety drugs and live virus vaccines. Pharm Purch Prod, 20(4), p.12. Click here Petrich, J., Marchese, D., Jenkins, C., Storey, M. and Blind, J., 2020. Gene replacement therapy: a primer for the health-system pharmacist. Journal of Pharmacy Practice, 33(6), pp.846-855. Click here Wang, A., Ngo, Z., Yu, S.J. and MacDonald, E.A., 2025. Implementing standard practices in the safe handling of gene therapy and biohazardous drugs in a health-system setting. American Journal of Health-System Pharmacy, p.zxaf026. Click here   VerifiedRx Listener Feedback Survey: We would love to hear from you - Please click here   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed

On this episode of Managed Care Cast, The American Journal of Managed Care® spoke with Gen Li, PhD, CEO and cofounder of Phesi, a clinical data company that provides AI-driven insights to sponsors and providers to optimize clinical trial efficacy. A recent analysis from Phesi found over 100 diseases currently being studied using GLP-1 RA therapies. The rapid growth of GLP-1 RA therapies being used across multiple, overlapping conditions creates an incentive for efficient and easily accessible clinical trial data to aid sponsors and researchers in establishing control cohorts using Phesi's Trial Accelerator platform and digital patient profiles.

Are cell therapies the key to bridging the gap between discovery research and clinical trials? In the inaugural episode of the Bioprocessing Unfiltered podcast, Bo Wiinberg, chief business development officer at Novo Nordisk Foundation Cellerator, sat with Ran Zheng, CEO of Landmark Bio and shared his expert insight on the promise cell therapies hold for diseases with only treatments but no cures. Their conversation covers the challenges of navigating cell therapy programs through pre-clinical and clinical development journeys, how Cellerator is creating innovative spaces in CMC and manufacturing to fulfill critical needs in the translational space, and what a sustainable global cell therapy manufacturing landscape looks in 5-10 years. Links from this episode:  Bioprocessing SummitLandmark BioNovo Nordisk Foundation Cellerator Bioprocessing Unfiltered: Covering both upstream and downstream processing, analytics, AI and digitization, cell and gene therapy and more, Bioprocessing Unfiltered is your insider's pass to the researchers tackling—and solving—the day-to-day challenges in the bioprocessing industry.Evaluating Biopharma boiler: Evaluating Biopharma taps into the insight and experience of biopharmaceutical leaders so today's decision makers can leverage their knowledge, learn from their successes, and avoid repeating similar mistakes. This series offers a new guest and moderator with each episode and aims to equip executives and science leaders with the necessary information to make better business and process decisions. The Evaluating Biopharma podcast is a reproduction of content originally presented at recent Evaluating Biopharma digital and educational networking events.

Meet Lauren and Alex from Hummingbird Pediatric Therapies, two passionate professionals revolutionizing care for young people with disabilities. Their multidisciplinary approach spans three Illinois locations, offering everything from occupational and physical therapy to innovative programs like hippotherapy. What makes them unique? They're filling critical gaps between pediatric and adult services through their Therapeutic Life Skills program, while their Intensive Therapy approach delivers more progress in three weeks than traditional therapy models achieve in months.The conversation takes a candid turn when discussing healthcare hurdles. "It's very frustrating when you know something's working or that a family could benefit from something," Lauren shares, detailing how insurance limitations often restrict access to life-changing services. These frustrations mirror my own journey after becoming paralyzed in a car accident, when insurance approved just three hours of care daily despite needing round-the-clock assistance. We explore how finding the right support—like my occupational therapist who introduced me to a game-changing mouse stick—can transform lives through what Alex beautifully describes as "inch stones over milestones."Whether you're navigating disability yourself, supporting someone who is, or simply curious about innovative approaches to therapy, this episode offers raw perspectives on overcoming systemic barriers with creativity and determination. Because as I remind listeners: "I'm paralyzed from the neck down breathing through a machine, but that doesn't stop me from following my dreams and doing what I love to do. I don't got any excuse, and neither should you."

Hunter syndrome is caused by the body's inability to produce a critical enzyme needed to break down cellular waste. The condition can cause damage to organs throughout the body as well as to the brain. A new generation of therapies in development, including a gene therapy currently under review by the U.S. Food and Drug Administration, that has the potential to address the neurological symptoms of the disease. Still, patient advocates have been frustrated by regulatory delays and are seeking to push the FDA and Congress to take action. We spoke with Kristin McKay, CEO of the Hunter syndrome patient advocacy organization Project Alive, about the need for new therapies, the importance of early detection, and the patient community's concerns with regulatory delays in approving needed treatments. An editor's note: Since recording this podcast, the FDA granted accelerated approval to Stealth Biotherapeutics' Forzinity for Barth syndrome, which is referenced in the discussion.

Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the effectiveness and safety of upadacitinib with secukinumab and adalimumab' and ‘the efficacy of long-term treatment with risankizumab across the updated GRAPPA domains and key related conditions of PsA'.

Beyond the Calcium Score: Longevity & Your Own Stem CellsClick On My Website Below To Schedule A Free 15 Min Zoom Call:www.Over40FitnessHacks.comOver 40 Fitness Hacks SKOOL Group!Get Your Whoop4.0 Here!Dr. Khoshal Latifzai - Rocky Mountain Regenerative Medicinewww.RMRM.comGuest: Dr. Kal Khoshal, MD (Rocky Mountain Regenerative Medicine, Boulder, CO) Focus: Longevity, prevention-first diagnostics, and regenerative therapies (peptides, hormones, PRP, stem cells).Origin story & model: After Dartmouth Med and a Yale EM residency, Dr. Khoshal left the ER due to burnout and the “band-aid” nature of conventional care. He built a cash-pay concierge clinic to spend 60–90 minutes with patients, run deeper diagnostics, and create long-term, prevention-focused plans. He does not bill insurance (patients keep catastrophic coverage), which lets him order better tests and avoid the admin churn.Diagnostics that actually predict risk:Starts from top U.S. mortality drivers (cardiovascular disease, diabetes, cancer, trauma in older adults) and then chooses biomarkers that best reflect true risk, repeating them multiple times per year and explaining results in plain English with written notes.Cancer screening: uses blood tests that detect circulating tumor DNA (ctDNA) as an early, broad screen; positives are followed by imaging (often full-body MRI or targeted MRI/PET).Heart disease: warns that calcium-score CT can miss early non-calcified plaque (common in 40s–60s). Prefers imaging that sees soft plaque before calcification.Whole-body MRI: advocates this for catching issues (like leg artery disease) that localized scans miss—especially relevant to older adults.Therapies & philosophy:Tools include peptides, hormones, PRP, and stem cells, but only after foundations: exercise, nutrition, and social health—there's no shortcut.Stem cells: strongly prefers autologous (your own) cells that are culture-expanded in a sterile lab, stored, and used over time (IV for systemic repair; guided injections for joints/spine).Cautions against routine allogeneic (donor/cord) cells due to immune reactions and potential long-term autoimmunity.Banking earlier is better, but even older adults can benefit; he shared an 80-year-old scoliosis case that avoided major spine surgery after one procedure.In-clinic process: mini-lipo harvest → lab isolation & expansion → cryostorage (annual maintenance fee ~$350).Advises skepticism about overseas clinics and some cord-blood banks with variable quality/control.If you're interested in online personal training or being a guest on my podcast, "Over 40 Fitness Hacks," you can reach me at brad@over40fitnesshacks.com or visit my website at:www.Over40FitnessHacks.comAdditionally, check out my Yelp reviews for my local business, Evolve Gym in Huntington Beach, at https://bit.ly/3GCKRzV

On this episode of the ATS Breathe Easy podcast, host Amy Attaway, MD, of Cleveland Clinic, continues her discussion with asthma expert Njira Lugogo, MD, of University of Michigan. They talk about collaborations in the pulmonary field, the importance of clinical trials, and career advice for those looking to join the field of pulmonology. In case you missed it, check out part one here: https://www.youtube.com/watch?v=4ubMlFuqsVI 

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AQV865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until September 28, 2026.Visual Exploration of the Evolving Role of Novel Oral SERDs, Other ER-Targeting Therapies, and Rational Combinations in ER+, HER2- MBC In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and METAvivor. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

In this episode of The Birth Lounge Podcast, HeHe sits down with clinical pharmacist Dr. Michaela Wachal to unpack the controversy surrounding Tylenol (acetaminophen) use in pregnancy and its potential links to autism and other neurodevelopmental concerns. Together, they dive into what the research actually says (and doesn't say), why transparency and informed consent are so important, and how to navigate decisions around medications in pregnancy with confidence. Dr. Wachal also highlights the bigger picture, like how genetics, environmental toxins, and even maternal stress can play a role in outcomes, and why caring for yourself is just as critical as any prescription. This conversation is packed with nuance, evidence, and practical takeaways to help you feel informed, empowered, and ready to advocate for yourself as you make decisions about your pregnancy care. 00:00 Introduction and Media Misrepresentation 01:05 Personal Story and Birth Lounge App 02:16 Empowering Prenatal Conversations 05:26 Emergency Use Authorization Episode 07:34 Interview with Dr. Michaela Wachal 09:14 Medication Safety in Pregnancy 12:37 Pharmaceutical Industry Failures 15:20 Personal Journey and Advocacy 18:55 Questioning Medical Norms 21:15 Tylenol and Toxins 23:34 Aluminum in Vaccines 27:32 The Importance of Transparency 37:05 Advocating for Education and Understanding 37:51 The Power of Asking Questions 40:21 Nesting and Preparing for Baby 43:17 Managing Fevers During Pregnancy 52:01 Environmental Toxins and Health 01:00:41 Therapies and Support for Children on the Spectrum 01:09:27 Final Thoughts and Encouragement   Guest Bio: Michaela Wachal, PharmD, CSP, is a clinical pharmacist, Certified Specialty Pharmacist, and Clinical Accreditation Manager with nearly a decade of experience in specialty pharmacy. She holds a Doctor of Pharmacy degree from the University of Nebraska Medical Center and a Bachelor of Science in Biochemistry from Doane University. Throughout her career, she's specialized in complex conditions including oncology, fertility, endocrinology, immunology, mental health, and inflammatory diseases—always with a passion for improving patient care, optimizing healthcare systems, and empowering women in medicine. Michaela is also a mom of three, including one child with autism, ADHD, and anxiety, which ignited her deep interest in neurodiversity, integrative health, and individualized medicine. After navigating her own family's challenges, she began researching functional and evidence-based approaches to support children and families living with complex needs. Online, Michaela shares insights from scientific studies on autism, ADHD, vaccines, autoimmune conditions, toxins, and more, always with a focus on helping parents make informed, evidence-based choices. Her work blends professional expertise with personal passion, making her a trusted voice in both the pharmacy world and the parenting community.   INSTAGRAM: Connect with HeHe on IG  Connect with Dr. Wachal on IG    BIRTH EDUCATION: Join The Birth Lounge here for judgment-free childbirth education that prepares you for an informed birth and how to confidently navigate hospital policy to have a trauma-free labor experience!   Download The Birth Lounge App for birth & postpartum prep delivered straight to your phone!   RESEARCH MENTIONED: 2021 there's a call for action published supported by 91 scientists, clinicians and public health professionals across the globe recommended that pregnant women should be cautioned at the beginning of pregnancy to forego APAP unless it is medically indicated and to minimize the exposure by using the lowest effective dose for shortest possible time https://pubmed.ncbi.nlm.nih.gov/34556849/   Boston Birth cohort published in 2020 looked at acetaminophen metabolites in cord blood samples collected at birth and unchanged acetaminophen levels were detected in all cord plasma samples and acetaminophen burden was associated with higher odds of ADHD  and ASD daignosis there was a 2.3 to 3.5 increased risk for ADHD and 1.6 to 4.1 increased risk for ASD https://pubmed.ncbi.nlm.nih.gov/31664451/   Recently in August Harvard did an analysis using the Navigation Guide methodology that supports evidence consistent with an association between acetaminophen exposure during pregnancy and increased incidence of Neurodevelopmental disorders. This included 46 studies with 27 reporting positive associations with the higher quality studies more likely to show positive correlations https://ehjournal.biomedcentral.com/articles/10.1186/s12940-025-01208-0   Nurses Health Study https://pubmed.ncbi.nlm.nih.gov/30923825/ Spanish birth cohort where acetaminophen exposure was associated with more hyperactivity/impulsivity https://pubmed.ncbi.nlm.nih.gov/27353198/   In 2018 there was a review that showed that 9 prospective cohort studies that all suggested an association between prenatal APAP exposure and neurodevelopmental outcomes - ADHD, ASD or lower IQ and longer duration was associated with increased risk https://pubmed.ncbi.nlm.nih.gov/29341895/   2022 a prospective cohort study in Pennsylvania looked at 2,423 moms using data and children who were exposed to APAP during pregnancy scored higher for child behaviors, sleep problems and attention problems  https://pubmed.ncbi.nlm.nih.gov/36170224/ Keywords: Tylenol pregnancy, acetaminophen pregnancy, Tylenol autism risk, pregnancy medication safety, prenatal care, evidence-based pregnancy, maternal health, neurodevelopment, pregnancy decision making, informed consent pregnancy, pregnancy medications, Dr. Michaela Wachal, Birth Lounge podcast, pregnancy self-care, pregnancy toxins

Sickle cell disease was once considered an incurable disease, until recently. A wide variety of gene therapies have now become available, allowing patients with sickle cell disease to now have futures once thought unimaginable. In this podcast episode, we talk through these treatments and get expert advice on what these treatments mean for our future. 

Drs. Hindiyeh and Hutchinson review new FDA-issued safety warnings for Raynaud's phenomenon and hypertension in CGRP-based migraine treatment. They explore the impact of this label update and share practical strategies for patient management.

Nicotine for memory? Methylene blue for mitochondria? Dr. Josh Axe breaks down 10 controversial compounds—what the science says, what's overhyped, and the key safety and legality questions to ask before you even think about trying them. Watch The Dr. Josh Axe Show every Monday & Thursday on YouTube: https://www.youtube.com/@drjoshaxe?sub_confirmation=1 

Why You Should Listen:  In this episode, you will learn about breakthrough therapies for chronic illness recovery including EBOO and TPE. About My Guest: My guest for this episode is Dr. Tami Lyday.  Tami Lyday, DO, MS has been a physician since 2006 and a functional and integrative specialist since 2017.  Prior to that, she spent 11 years as a family practitioner but was never quite satisfied with conventional medical approaches.  Her mother's illness and subsequent side effects of traditional treatments prompted her to learn more about integrative medicine, and she has not looked back.  Dr. Lyday believes functional and integrative medicine is the best way to ensure lasting recovery as it helps patients determine the root of their health issues and does not rely on medications that treat symptoms while ignoring the underlying causes of illness.  She pursued training and certifications in functional and integrative medicine, including specialty training and certifications in the treatment of mold-related illnesses and Lyme disease. At the time of her certification, she was one of only 26 practitioners in the world who were Shoemaker certified in mold treatment protocols.  After 4 years as a functional and integrative medical practitioner, she opened The Lyday Center to provide a dedicated resource for people who are suffering from mystery illnesses and ailments that don't respond to conventional treatment and are seeking natural solutions to their chronic illnesses.  Since that time, she has expanded her specialties to include the treatment of thyroid disorders and overall energy levels.  Her mission is to heal the world one patient at a time. Key Takeaways: How much does environmental toxicity contribute to chronic illness? How is a patient tested for mold illness? What binders are most commonly used for detoxification?  Do natural binders have a place? What is the role of Actinobacteria and endotoxins in CIRS patients? Can a patient have fungal colonization and potentially benefit from antifungals? Does treating mold also treat Lyme and coinfections? How important is working on the limbic system to set the stage for healing? How might EBOO and TPE support those with autoimmunity? Where in a recovery timeline do EBOO and TPE best fit? Does Hashimoto's occur without mold? What is the role of EBOO?  What is the EBOO process? What is done before and after EBOO to support the patient? Can patients have detoxification or Herxheimer reactions after EBOO or TPE? How might EBOO and TPE help those with Long COVID? What types of infections might EBOO support? What is the role of TPE?  What is the TPE process? What types of toxicants and toxins can be filtered out? How is the removed plasma replaced Might beneficial materials be removed with TPE? Can EBOO or TPE help those with neurodegenerative conditions? Connect With My Guest:  TheLydayCenter.com Interview Date: September 5, 2025 Transcript: To review a transcript of this show, visit https://BetterHealthGuy.com/Episode222. Additional Information: To learn more, visit https://BetterHealthGuy.com. Follow Me on Social Media: Facebook - https://facebook.com/betterhealthguy Instagram - https://instagram.com/betterhealthguy X - https://twitter.com/betterhealthguy TikTok - https://tiktok.com/@betterhealthguy Disclaimer:  The content of this show is for informational purposes only and is not intended to diagnose, treat, or cure any illness or medical condition. Nothing in today's discussion is meant to serve as medical advice or as information to facilitate self-treatment. As always, please discuss any potential health-related decisions with your own personal medical authority.